greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2021

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2021: revenue JPY 3,198 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2021 it reported revenue of JPY 3,198 billion ($30.1 billion at the year's average rate), down 2.8% on the year before. Its profit attributable to shareholders was JPY 376 billion, up 749.9%, and diluted earnings per share JPY 238.96.

Revenue
JPY 3,198 billion
-2.8% on the year
FY2017FY2021
Operating margin
15.9%
3.1% a year earlier
FY2017FY2021
Net income
JPY 376 billion
+749.9% on the year
FY2017FY2021
Diluted EPS
JPY 238.96
+745.9% on the year
FY2017FY2021

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2020Mar 2021
Revenue3,2913,198
Cost of sales1,090994
Research and development492456
Operating profit100509
Finance costs165249
Profit before tax-60.8366
Income tax-105-9.9
Profit for the year44.3376
Profit attributable to shareholders44.2376
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2020Mar 2021
Diluted EPS28.25238.96
Basic EPS28.41240.72
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2020Mar 2021
Cash from operations6701,011
Purchase of property, plant and equipment127111
Free cash flow543900
Cash from investing292394
Cash from financing-1,005-1,088
Depreciation and amortisation584560
Buybacks3.72.1
Dividends paid283283
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2020Mar 2021
Funded by
Equity attributable to shareholders4,7235,173
Non-controlling interests4.04.1
Borrowings, as filed5,0934,635
Lease liabilities369436
Other liabilities2,6312,663
Total equity and liabilities12,82112,912
Owned
Property, plant and equipment1,3861,454
Goodwill4,0134,034
Other intangible assets4,1713,909
Cash and cash equivalents638966
Trade and other receivables757783
Inventories760754
Other assets1,0971,012
Total assets12,82112,912
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2020Mar 2021
Operating margin3.1%15.9%
Net margin1.3%11.8%
Free cash flow margin16.5%28.1%
Return on year-end equity0.9%7.3%
Effective tax raten/a-2.7%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2021, filed 28 June 2023: the filing. The figures are in yen as filed.